Cargando…

Recent advances in treatments of adult immune thrombocytopenia

Immune thrombocytopenia (ITP) is isolated thrombocytopenia characterized by autoimmune-mediated disruption of platelet without other etiologies. Treatments for chronic ITP consist of corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, thrombopoietin receptor agonists, imm...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kim, Dae Sik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057657/ https://www.ncbi.nlm.nih.gov/pubmed/35483935 http://dx.doi.org/10.5045/br.2022.2022038

Ejemplares similares

Recent advances in the mechanisms and treatment of immune thrombocytopenia
por: Provan, Drew, et al.
Publicado: (2022)

Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments
por: Audia, Sylvain, et al.
Publicado: (2021)

Advances in Diagnosis and Treatments for Immune Thrombocytopenia
por: Nomura, Shosaku
Publicado: (2016)

Recent advances in understanding and management of acquired thrombocytopenia
por: Nagalla, Srikanth, et al.
Publicado: (2018)

Evolving treatment modalities for immune thrombocytopenia in adults
por: Khadka, Sushmita, et al.
Publicado: (2021)

Current and evolving treatment strategies in adult immune thrombocytopenia
por: Bohn, Jan-Paul, et al.
Publicado: (2018)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome
por: Carré, Julie, et al.
Publicado: (2021)

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations
por: Park, Young Hoon, et al.
Publicado: (2022)

Older Adults and Immune Thrombocytopenia: Considerations for the Clinician
por: Crickx, Etienne, et al.
Publicado: (2023)

Treatment of drug-induced immune thrombocytopenias
por: Marini, Irene, et al.
Publicado: (2022)

How we treat primary immune thrombocytopenia in adults
por: Liu, Xin-guang, et al.
Publicado: (2023)

Efgartigimod alfa for the treatment of primary immune thrombocytopenia
por: Broome, Catherine
Publicado: (2023)

Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern
por: Cuker, Adam, et al.
Publicado: (2021)

Biomarkers for immune thrombocytopenia
por: Yu, Lingjia, et al.
Publicado: (2015)

Advances in management of pediatric chronic immune thrombocytopenia: a narrative review
por: Lee, Jae Min
Publicado: (2023)

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
por: Cheung, Eric, et al.
Publicado: (2009)

Romiplostim as a treatment for immune thrombocytopenia: a review
por: Chalmers, Sarah, et al.
Publicado: (2015)

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia
por: Lambert, Michele P
Publicado: (2016)

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
por: Janssens, Ann, et al.
Publicado: (2016)

T cell immune abnormalities in immune thrombocytopenia
por: Ji, Xuebin, et al.
Publicado: (2014)

Systematic literature review of treatments used for adult immune thrombocytopenia in the second‐line setting
por: Bylsma, Lauren C., et al.
Publicado: (2018)

Review: Advances in the Pathogenesis and Treatment of Immune Thrombocytopenia Associated with Viral Hepatitis
por: Xu, Yanmei, et al.
Publicado: (2023)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
por: Gilbert, Megan M, et al.
Publicado: (2020)

Emerging Therapies in Immune Thrombocytopenia
por: Audia, Sylvain, et al.
Publicado: (2021)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Recent advances in the treatment of adult T-cell leukemia-lymphomas
por: Utsunomiya, Atae, et al.
Publicado: (2015)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
por: Tsykunova, Galina, et al.
Publicado: (2022)

Recent advances in laryngoscopy in adults
por: Parotto, Matteo, et al.
Publicado: (2019)

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
por: Lucchini, Elisa, et al.
Publicado: (2019)

Recent advances in understanding antitumor immunity
por: Munhoz, Rodrigo Ramella, et al.
Publicado: (2016)

Recent advances in understanding rhinovirus immunity
por: Makris, Spyridon, et al.
Publicado: (2018)

Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand
por: Choi, Philip YI, et al.
Publicado: (2021)

Current Management of Primary Immune Thrombocytopenia
por: Provan, Drew, et al.
Publicado: (2015)

Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome
por: Königshausen, Eva, et al.
Publicado: (2017)

Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia
por: Datta, Payel, et al.
Publicado: (2021)

Imbalance of T Lymphocyte Subsets in Adult Immune Thrombocytopenia
por: Lin, Xiuxiu, et al.
Publicado: (2021)

Inherited thrombocytopenias: history, advances and perspectives
por: Nurden, Alan T., et al.
Publicado: (2020)

Research Advances in the Subtype of Sepsis-Associated Thrombocytopenia
por: Wu, Xinghui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u37l7g7h73gkp4mf2u2ce505i6